Project Details
Projekt
Notch signaling as a novel target of AML/ETO (A03)
Subject Area
Hematology, Oncology
Term
from 2012 to 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 217328187
The alternative splice variant of t(8;21) AML-ETO9a (AE9a) induces leukemia in mouse models upon retroviral transduction. However, analyses of patient data revealed no prognostic impact of AE9a expression in t(8;21)-positive AML patients. In addition, a novel conditional AE9a mouse model does develop leukemia. This suggests the requirement of additional “hits” for AE9a-driven leukemia. To identify those, retroviral insertional mutagenesis as well as biological/biochemical and clinical validation will be performed. In parallel, we want to decipher the contribution of a dysregulated Notch signaling pathway to AML onset using small molecule compounds that specifically modulate Notch signaling activity.
DFG Programme
Collaborative Research Centres
Applicant Institution
Universität Ulm
Project Heads
Professor Dr. Hartmut Geiger; Professor Dr. Franz Oswald
